

Aminocaproic Acid Tablets, USP 500mg

| S.No. | Category | Question | Answer | | | | |
|--------|----------------------|------------------------------------|---|--|--|--|--|
| 5.INU. | Category | | | | | | |
| | Clinical Particulars | | | | | | |
| 1 | Use/Indication | What is the product indicated for? | Aminocaproic acid tablets, USP is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life- threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Take Aminocaproic Acid Tablets exactly as your doctor tells you to take it. | | | | |
| 2 | Dosage | What is the recommended dosage? | For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 aminocaproic acid tablets 1000 mg Tablets or 10 aminocaproic acid tablets 500 mg Tablets (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 aminocaproic acid tablets 1000 mg Tablet or 2 aminocaproic acid tablets 500 mg Tablets (1 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled. | | | | |
| 3 | Administration | How do I take it? | Take Aminocaproic Acid Tablets exactly as your doctor tells you to take it. | | | | |
| 4 | Formulation | Can tablet be crushed? | Take Aminocaproic Acid Tablets exactly as your doctor tells you to take it. | | | | |
| 5 | Administration | What do I do if I miss a dose? | If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time. Please contact your physician for further queries. | | | | |
| 6 | Administration | Use in Pediatric Population | Safety and effectiveness in pediatric patients have not been established. | | | | |
| 8 | Mechanism | Mechanism of Action | Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. | | | | |
| 9 | Warning | Black Box Warning | None | | | | |
| 10 | Lactation | Use in Lactation | It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman. | | | | |
| 11 | Pregnancy | Use in Pregnancy | Aminocaproic Acid Tablets are categorised Pregnancy Category C: Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed. | | | | |



| interaction with food? 4 Side effects What are the common side effects? Adverse reactions were reported with Aminocaproic acid reactions, anaphylaxis, bradycardia, hypotension, peripheral ischemia, thrombosis, abdomial pain, diarrhea, nausea, vomiting, agranulozytosis, coagulation disorder, leukopenia, thrombocytopenia, CPK increased, muscle weakness, myalgia, myopathy, myositis, rhabdomylysis, confusion, convulsions, delirtum, dizzines, hallucinations, intracranial hypertension, stroke, syncope, dyspnea, nasal congestion, pulmonary embolism, puritis, rash, timitus, vision decreased and watery eyes. 5 Storage What are the storage conductors? Store at 20° to 25°C (66° to 77°F); Dispense in Tight Containers. 6 Dispensing How to Dispense? Dispense in Tight Containers. 7 Contraindication What are the storage of (medication). Aminocaproic acid should not be used when there is evidence of an active intravascular cloting processes. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis. Platelet count is usually decreased in DIC but normal in primary fibrinolysis. 7 Contraindication What are the used when there is a cacid must not be used in the presence of DIC without concomitant heparin. 8 Pharmaceutical Particular Processed in DIC at minocaproic acid. The euglobulin dclt ty is test is abnormal in primary fibrinolysis. 9 Ingredients Active and Inactive Ingredients Active: Aminocapro | 12 | Precautions | Is there any | None |
|--|----|------------------|---------------------------------------|--|
| 3 Interaction is there any interaction with food? 4 Side effects What are the common side effects? Aminocaproic acid is generally well tolerated. The following adverse reactions were reported with Aminocaproic acid: edema, headache, malaise, allergic and anaphylactid reactions, anaphylaxis, bradycardia, mypotension, peripheral ischemia, thrombosis, abdominal pain, diarthea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopenia, thrombosis, abdomala pain, diarthea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopenia, thrombosis, abdomaly pain, diarthea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopenia, thrombosis, abdomaly pain, diarthea, nausea, vomiting, agranulocytosis, coagulation, disorder, leukopenia, thrombosis, abdimum, dizziness, hallucinations, intracranial hypertension, storke, syncope, dyspnea, nasal confusion, pulmonary embolism, pruntis, rash, linnitus, vision decreased and watery eyes. 5 Storage What are the storage contraindications of (medication). Dispense in Tight Containers. 7 Contraindication of (medication). How to Dispense? Dispense in Tight Containers. 8 Pharmaceutical Phatelect court is usually decreased in DIC but normal in primary fibrinolysis. 9 Ingredients Active and Inactive Ingredients Each white to olf white colored, round shaped, uncoated tablets with break line debossed with "MA1" and "17" on ore side and plain on ther side, contains 500 mg of aminocaproic acid. 9 Ingredients Act | | | medication and | |
| common side effects? adverse reactions we're reported with Aminocaproic acid edema, headache, malaise, allergic and anaphylactoid reactions, anaphylaxis, bradycardia, hypotension, peripheral ischemia, thrombosis, abdominal pain, diarrhea, nussea, vomiting, agranulocytosis, coagulation disorder, leukopenia, thrombosyto, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnea, nasal congestion, pulmonary embolism, pruritis, rash, tinnitus, vision decreased and watery eyes. 5 Storage What are the storage conditions? Dispense in Tight Containers. 6 Dispensing How to Dispense? Dispense in Tight Containers. 7 Contraindication What are the contraindications of (medication). Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. 1 The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. 8 Pharmaceutical Form How is it supplied? Each white to off white colored, round shaped, uncoated tablets with preak line debossed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid 9 Ingredients Active and Inactive Ingredients Active and Inactive Inactive: colloidal silicoon dioxide, c | 13 | Interaction | Is there any | None |
| conditions? Containers; Do Not Freeze. 6 Dispensing How to Dispense? Dispense in Tight Containers. 7 Contraindication What are the contraindications of (medication). Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: 9 Pharmaceutical How is it supplied? Each white to off white colored, round shaped, uncoated tablets with break line debosed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid. 9 Ingredients Active and Inactive Ingredients Active: colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone and stearic acid. 00 Coating What is the type of Uncoated tablets | 14 | Side effects | | adverse reactions were reported with Aminocaproic acid: edema, headache, malaise, allergic and anaphylactoid reactions, anaphylaxis, bradycardia, hypotension, peripheral ischemia, thrombosis, abdominal pain, diarrhea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia, CPK increased, muscle weakness, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnea, nasal congestion, pulmonary embolism, pruritis, rash, tinnitus, |
| 7 Contraindication What are the contraindications of (medication). Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Protamine Para coagulation test is positive in DIC; a precipitate form when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. • The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin. Pharmaceutical Form How is it supplied? Each white to off white colored, round shaped, uncoated tablets with break line debossed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid. Bottle of 30 – NDC 72205-049-30 9 Ingredients Active and Inactive Ingredients end thactive: colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone and stearic acid. 00 Coating What is the type of <t< td=""><td>15</td><td>Storage</td><td>J</td><td></td></t<> | 15 | Storage | J | |
| Image: space of the second state | 16 | Dispensing | How to Dispense? | Dispense in Tight Containers. |
| 8 Pharmaceutical Form How is it supplied? Each white to off white colored, round shaped, uncoated tablets with break line debossed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid. Bottle of 30 – NDC 72205-049-30 9 Ingredients Active and Inactive Ingredients Active: Aminocaproic acid Inactive: colloidal silicon dioxide, 90 Coating What is the type of Uncoated tablets | 17 | Contraindication | contraindications of (medication). | evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine Para coagulation test is positive in DIC; a precipitate form when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. |
| Formtablets with break line debossed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid. Bottle of 30 – NDC 72205-049-309IngredientsActive and Inactive IngredientsActive: Aminocaproic acid9IngredientsActive and Inactive IngredientsActive: Colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone and stearic acid.90CoatingWhat is the type of Uncoated tablets | | | | |
| Ingredients Inactive: colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone and stearic acid. 0 Coating What is the type of Uncoated tablets | 18 | | How is it supplied? | tablets with break line debossed with "MA" and "17" on one side and plain on other side, contains 500 mg of aminocaproic acid. |
| | 19 | | Ingredients | Inactive : colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone and stearic acid. |
| | 20 | Coating | coating? | |
| Allergens | | | | |



| 21 | Ingredients | Is it Vegetarian? | AN (MSND COMPANY Yes, Free from Animal Products/Derivatives. |
|----|---------------|--------------------------------------|--|
| 22 | Ingredients | Does it contain | No |
| | ingreaterite | Gluten? | |
| 23 | Ingredients | Does it contain Dairy Products? | No |
| 24 | Ingredients | Does it contain Casein | No |
| 25 | Ingredients | Does it contain Whey? | No |
| 26 | Ingredients | Does it contain corn? | No |
| 27 | Ingredients | Does it contain rye? | No |
| 28 | Ingredients | Does it contain sugar? | No |
| 29 | Ingredients | Does it contain Oats? | No |
| 30 | Ingredients | Does it contain wheat? | No |
| 31 | Ingredients | Does it contain spelt? | No |
| 32 | Ingredients | Does it contain barley? | No |
| 33 | Ingredients | Does it contain rennet? | No |
| 34 | Ingredients | Does it contain starch? | No |
| 35 | Ingredients | Does it contain povidone? | Yes, Inactive ingredients included povidone. |
| 36 | Ingredients | Does it contain lodine? | Yes, Inactive ingredients included crospovidone, which is povidone-iodine complex. |
| 37 | Ingredients | Does it contain latex? | No |
| 38 | Ingredients | Does it contain alcohol? | Yes, Aminocaproic acid API contains Iso-propyl alcohol NMT 2000 PPM |
| 39 | Ingredients | Does it contain dyes? | No |
| 40 | Ingredients | Does it contain flavor? | No |
| 41 | Ingredients | Does it contain Lactose? | No |
| 42 | Ingredients | Does it contain Nuts? | No |
| 43 | Ingredients | Does it contain Preservatives? | No |
| 44 | Ingredients | Does it contain Soy products? | No |
| 45 | Ingredients | Does it contain peanut? | No |
| 46 | Ingredients | Does it contain nickel? | No |
| | | | cellaneous |
| 47 | Miscellaneous | May I know the product availability? | Novadoz Pharmaceuticals products are only available through pharmacies, wholesalers, and other authorized distributors. See our ADR (authorized distributors of record) page at NovadozPharma.com to learn more about where to find our products |



| MC II | | Outline New Les Discusses (Sector Outline Outline |
|---------------|------------------------|---|
| Miscellaneous | 5 | |
| | | directly at 908-360-1500 |
| | reimbursement? | |
| Miscellaneous | Do you have any | Novadoz Pharmaceuticals does not offer patient assistance |
| | patient's assistance | programs at this time. The company that produces the |
| | program? | brand version of your product may or may not offer such a |
| | | program. Please check for access & eligibility |
| | | requirements with that company. |
| Miscellaneous | How do I report an | To report suspected adverse reactions, contact Novadoz |
| | adverse drug effect or | Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800- |
| | reaction to Novadoz | FDA-1088 or www.fda.gov/medwatch. |
| | medication? | |
| Miscellaneous | Why does my | Please check with your pharmacy as to why your |
| | pharmacy that used | prescription is not a Novadoz Pharmaceuticals |
| | to fill your generic | product. You may refer to NovadozPharma.com ADR |
| | formulation of a | (authorized distributor of record) page to learn where to find |
| | particular medicine, | our products. |
| | no longer fills my | |
| | | |
| | Novadoz formulation? | |
| Miscellaneous | Manufacturer and | Manufactured by: |
| | Distributor | MSN Laboratories Private Limited |
| | | Telangana – 509 228, |
| | | INDIA |
| | | Distributed by: |
| | | Novadoz Pharmaceuticals LLC |
| | | Piscataway, NJ 08854-3714 |
| | | Issued on: 02/2020 |
| | Miscellaneous | Miscellaneousrefurn, refunds and reimbursement?MiscellaneousDo you have any patient's assistance program?MiscellaneousHow do I report an adverse drug effect or reaction to Novadoz medication?MiscellaneousWhy does my pharmacy that used to fill your generic formulation of a particular medicine, no longer fills my prescription with Novadoz formulation?MiscellaneousManufacturer and |